Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05467891
Title Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR)
Acronym RaPhLRR
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Oana Danciu
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.